Hilborn originally stepped into the interim CFO role in September 2025, having previously served as the company’s vice president of finance since July 2024. His background includes professional tenures at Telus, EY, and PricewaterhouseCoopers, providing a foundation in accounting and corporate financial management that the organization aims to leverage as it navigates the biopharmaceutical sector.
Avicanna Appoints Nick Hilborn as Permanent CFO
After holding the position on an interim basis for several months, Nick Hilborn has been officially appointed chief financial officer of the Canadian biopharmaceutical firm Avicanna. His elevation to the permanent role follows a strategic transition period intended to solidify the company's fiscal leadership and long-term financial oversight.
Comments (0)
No comments yet. Be the first!